Status:
COMPLETED
Self-management of Low Molecular Weight Heparin Therapy
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
Pfizer
Conditions:
Thromboembolism
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
There is very little data available on compliance with self-injected low molecular weight heparins (LMWH), but what there is, definitely shows that compliance represents a significant problem. We ther...
Detailed Description
Patient recruitment in community pharmacies enables the testing of the feasibility of the interventions under daily-practice conditions and facilitates the recruitment of a larger number of patients. ...
Eligibility Criteria
Inclusion
- Patients are recruited from orthopedic clinics, an emergency department and from community pharmacies with a prescription for a LMWH as an outpatient treatment.
- self-application of the LMWH
- german / english speaking
- \> clinical setting:
- Dalteparin
- \> daily life setting:
- all LMWH (ready-to-use syringes)
- control group: self-application or application by another person (family member, medical person, etc.)
Exclusion
- \- patient's home far away from study center
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT00794560
Start Date
June 1 2007
End Date
August 1 2009
Last Update
November 18 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Basle, Switzerland
Basel, Switzerland, CH-4031
2
Kantonsspital Baselland, Switzerland
Bruderholz, Switzerland, CH-4101